Skip to content

PET-MRI Esophagus Feasibility Study

Feasibility Study of PET-MRI as a Platform for Image Guidance and Adaptive Radiation Therapy in Patients With Esophagogastric Cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05796102
Acronym
PET-MRI
Enrollment
15
Registered
2023-04-03
Start date
2023-03-28
Completion date
2027-05-01
Last updated
2026-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophagogastric Cancer

Brief summary

This is a single arm, single centre, investigator initiated study to investigate the feasibility of using PET-MRI imaging in radiation treatment workflow in up to 15 patients with esophagogastric cancer. PET-MRI imaging will be completed before the start of radiation treatment. MRI imaging will be completed during radiation treatment and after radiation treatment. These images will not be used to plan the radiation treatment and routine clinical care will be provided. The goal of this study is to gather information that will allow the radiation team to include MRI and PET imaging into the radiation treatment workflow for patients with esophageal cancer receiving radiation therapy in the future.

Interventions

PROCEDUREPET-MRI

A PET/MRI scan is a two-in-one test that combines images from a positron emission tomography (PET) scan and a magnetic resonance imaging (MRI) scan. Magnetic Resonance Imaging (MRI) provides better soft tissue contrast compared to conventional computerized tomography (CT), and when combined with PET, can potentially provide better visualization of the tumor shape, size, and position. Additional MRI imaging will be completed once during radiation treatment, and once after radiation treatment

Sponsors

University Health Network, Toronto
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients 18 years or older * Diagnosed with locally advanced esophageal cancer being considered for conventional RT \>4 weeks * Ability and willingness to provide written informed consent

Exclusion criteria

* Contraindication for MRI * Contraindication for Gadolinium (i.e. inability to lie supine for at least 60 minutes) * Any patient who is pregnant or breastfeeding * Pacemaker or implanted defibrillator * Claustrophobia

Design outcomes

Primary

MeasureTime frameDescription
Feasibility of PET-MRI to visualize and assess impact of RT treatments on esophagogastric tumors2 yearsDetection of metastases on DWI and gadolinium enhanced T1-weighted 3D VIBE sequences.

Secondary

MeasureTime frameDescription
Difference in manual GTV segmentation using PET-MRI2 yearsDifferences in manual GTV segmentation between standard of care treatment plan and study generated treatment plan using PET-MRI.
Quantification of dosimetric advantages of PET-MRI treatment plan2 yearsComparison of dosimetry properties between the standard of care treatment plan and study generated treatment plan using PET-MRI.

Countries

Canada

Contacts

CONTACTRebecca K S Wong, MD
rebecca.wong@uhn.ca4169462000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 6, 2026